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Chronic liver disease is associated with remarkable alterations in
the intra- and extrahepatic vasculature. Because of these
changes, the ﬁelds of liver vasculature and portal hypertension
have recently become closely integrated within the broader vas-
cular biology discipline. As developments in vascular biology
have evolved, a deeper understanding of vascular processes
has led to a better understanding of the mechanisms of the
dynamic vascular changes associated with portal hypertension
and chronic liver disease. In this context, hepatic vascular cells,
such as sinusoidal endothelial cells and pericyte-like hepatic
stellate cells, are closely associated with one another, where
they have paracrine and autocrine effects on each other and
themselves. These cells play important roles in the pathogenesis
of liver ﬁbrosis/cirrhosis and portal hypertension. Further, a vari-
ety of signaling pathways have recently come to light. These
include growth factor pathways involving cytokines such as
transforming growth factor b, platelet derived growth factor,
and others as well as a variety of vasoactive peptides and other
molecules. An early and consistent feature of liver injury is the
development of an increase in intra-hepatic resistance; this is
associated with changes in hepatic vascular cells and their sig-
naling pathway that cause portal hypertension. A critical con-
cept is that this process aggregates signals to the extrahepatic
circulation, causing derangement in this system’s cells and sig-
naling pathways, which ultimately leads to the collateral vessel
formation and arterial vasodilation in the splanchnic and sys-Journal of Hepatology 20
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cells.temic circulation, which by virtue of the hydraulic derivation
of Ohm’s law (pressure = resistance  ﬂow), worsens portal
hypertension. This review provides a detailed review of the cur-
rent status and future direction of the basic biology of portal
hypertension with a focus on the physiology, pathophysiology,
and signaling of cells within the liver, as well as those in the
mesenteric vascular circulation. Translational implications of
recent research and the future directions that it points to are
also highlighted.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-SA license.Introduction
Understanding of the basic elements of general and liver speciﬁc
vascular biology has grown substantially over the last decade.
This work has led to exciting new developments in the ﬁeld of
portal hypertension. This review aims to put these advances into
context.
Vascular beds are diverse, each with their own speciﬁc func-
tional attributes. Notwithstanding, a number of themes have
emerged. In patients with chronic liver disease, the peripheral
vasculature, the mesenteric vascular bed, and the intrahepatic
microcirculatory unit have received attention (Fig. 1). A recurrent
theme is that while the cells and molecules in each vascular
structure exhibit many similarities, variability in signaling path-
ways lead to unique functional attributes in each. For example,
in the sinusoid and liver, vasoconstriction and increased resis-
tance to blood ﬂow is prominent. In contrast, in the mesenteric
vasculature, vasodilation is prominent. The combination of
increased resistance in the liver and increased ﬂow to the portal
vein from the mesenteric circulation results in increased portal
pressure as indicated by the hydraulic equivalent of Ohm’s Law
(pressure = ﬂow  resistance). Additionally, it is important to rec-
ognise that factors other than the vascular bed itself may be
important in the development of changes in resistance or ﬂow.
For example, within the liver, it is likely that ﬁbrosis, particularly
in advanced states is critically important in the increased resis-
tance, typical of portal hypertension.14 vol. 61 j 912–924
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Intrahepatic vascular bed
• Increased gene and peptide expression of vasoconstrictors (ET-1, Ang II)
• Reduced eNOS phosphorylation, activity and NO production
• Increased resistance
• Increased pressure
• Reduced portal venous blood flow
Mesenteric vascular bed
• Reduced gene and peptide expression of vasoconstrictors (ET-1, Ang II)
• Increased eNOS phosphorylation, activity and NO production
• Decreased Rho kinase activity
• Increased expression of angiogenic factors (VEGF, PDGF, PlGF)
• Arterial vasodilation
• Arterial wall thinning
• Decreased response to vasoconstrictors
• Increased portal venous blood flow
Peripheral vasculature
• Increased eNOS phosphorylation, activity and NO production • Reduced resistance
• Decreased arterial response to vasoconstrictors
• Autonomic dysfunction
• Increased cardiac output
• Increased blood flow
Pulmonary vasculature (typical, not “portopulmonary changes”)
• Increased ET-1 gene and peptide production
• Increased ET-B receptor expression
• Increased eNOS phosphorylation, activity and NO production
• Pulmonary small vessel dilation 
• Extensive shunting, with left sided hypo-
oxygenation
• Increased cardiac output
Fig. 1. Heterogeneity of vascular beds in portal hypertension. Shown are prominent vascular beds and their associated pathophysiology. The intrahepatic vascular bed is
typiﬁed by an increase in resistance to ﬂow. Liver injury leads to abnormal endothelial function, with a reduction in the production of vasodilators by sinusoidal endothelial
cells such as nitric oxide (NO); concomitantly, there is an increase in the synthesis of vasoconstrictors such as endothelin-1 (ET1) and angiotensin II (Ang II) by other cells in
the sinusoid (see also Fig. 2). The mesenteric vascular bed is characterised by vasodilation by reduced resistance caused by upregulation of vasodilators such as NO, leading
to increased ﬂow to the portal vein. The net result of this physiology is an increase in intrahepatic resistance and portal blood ﬂow from the splanchnic circulation, leading
to increased portal pressure and portal hypertension. In peripheral vascular beds, increased eNOS activity and NO production typically leads to reduced resistance, low
systemic pressure, and a hyperdynamic state typical of patients with cirrhosis. Abnormalities also exist in other vascular beds such as the pulmonary, brain, renal, and likely
even others. Of note, increased intrahepatic resistance is only for the portal system, and the resistance of the hepatic artery is decreased. Therefore, due to the hepatic
arterial buffer response, the total blood ﬂow into the liver may be the same in cirrhosis [130]. ET-1, endothelin-1; Ang II, angiotensin II; NO, nitric oxide; eNOS, endothelial
nitric oxide synthase; VEGF, vascular endothelial growth factor; PDGF, platelet derived growth factor; PlGF, placental growth factor.
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ReviewKey Points
• Significant alterations in the intra- and extrahepatic 
vasculature are prominent in chronic liver diseases
• Hepatic vascular cells, such as sinusoidal endothelial 
cells and pericyte-like hepatic stellate cells, have 
paracrine and autocrine effects on each other 
and themselves, and play important roles in the 
pathogenesis of liver fibrosis/cirrhosis and portal 
hypertension
• An important feature of liver injury is development 
of an increase in intra-hepatic resistance, which is 
associated with alterations in hepatic vascular cells and 
their signaling pathway that causes portal hypertension
• Portal hypertension leads to the collateral vessel 
formation and arterial vasodilation in the splanchnic 
and systemic circulation, which worsens portal 
hypertension
• This review summarizes the current state and 
future directions in hepatic vascular biology and 
portal hypertension - with a focus on the physiology, 
pathophysiology of cells and molecules within the liver, 
as well as those in the mesenteric vascular circulation. 
Translational implications of current research are 
highlightedIntrahepatic vascular pathophysiology
The intrahepatic microvascular unit is made up of several dis-
crete units, including portal venules, hepatic arterioles, sinusoids,
central venules, and lymphatics. The cellular elements in these
structures include endothelial cells, smooth muscle cells, and in
the sinusoid, pericyte-like hepatic stellate cells. It is important
to recognise that these cells are intimately associated with one
another, where they have paracrine and autocrine effects on each
other and themselves. The canonical example of course is the par-
acrine effect of nitric oxide (NO), released by sinusoidal endothe-
lial cells on smooth muscle cells and on stellate cells.
Hepatic cells in intrahepatic vascular physiology and
pathophysiology
Liver sinusoidal endothelial cells (LSEC)
The majority of hepatic endothelial cells reside within the hepatic
sinusoids; these cells, known as liver sinusoidal endothelial cells
(LSECs), have therefore garnered great attention. The LSEC pheno-
type is uniquely different, not only from endothelial cells in other
portions of the liver, but also from endothelial cells in other
organs [1]. Perhaps the most unique feature of the LSEC pheno-
type is fenestration; fenestrae are organised in typical sieve
plates [2]. While the function of fenestrae is controversial, it
appears that they help facilitate the transport of macromolecules
from the sinusoidal lumen, across the cell, into the space of Disse,
providing access of these molecules to hepatocytes. Additionally,
in vivo, LSECs lack a typical basement membrane, further facilitat-
ing macromolecular transport [1,3].914 Journal of Hepatology 201A key signature of most forms of liver injury/disease is the loss
of many of these unique phenotypes. Additionally, it should be
emphasised that typical LSEC features are lost in culture, making
in vitro study of LSEC phenotypes challenging. It is well appreci-
ated that liver ﬁbrosis is associated with alterations in the diam-
eter and number of fenestrae [3]. A recent innovative structural
analysis [4] showed that fenestrae formation could be regulated
by membrane lipid rafts, which are cholesterol and sphingolipid
rich domains that serve as a platform for many membrane pro-
teins such as caveolin. Interestingly, fenestrae distribution
appears to be inversely related to lipid raft regions.
Recent work has begun to untangle the molecular signaling
pathways that lead from cell injury to abnormalities in fenestra-
tion. For example, exposure of LSECs to vascular endothelial
growth factor (VEGF) treatment increases fenestrae formation
by decreasing the abundance of lipid raft regions, which may
explain an essential role of VEGF for the maintenance of fenestrae
observed by others (see below). Furthermore, decreased fenestrae
formation may be linked to increased caveolin-1 levels observed
in LSEC after liver ﬁbrosis [5]. Further work to better understand
the pathways leading from injury and ﬁbrosis to fenestral abnor-
mality is expected.
Regulation of the LSEC phenotype. A variety of molecular signaling
pathways regulate the LSEC phenotype; these are both soluble
factors and mechanical forces. Among the soluble factors, growth
factors appear to be the most prominent. As referred to above,
VEGF appears to be the most critical molecule in the modulation
of the size and number of LSEC fenestrae [5–8]. Removal of VEGF
from the cell culture medium results in loss of fenestrae, which
can be restored by resupply of VEGF [6]. Similarly, disruption of
VEGF signaling by a conditional deletion of Vegfr1 in mice led
to loss of fenestrae, while restitution of VEGFR1 led to re-
fenestration [8]. A number of growth factors other than VEGF also
regulate the LSEC phenotype, with most of these being activators
of receptor tyrosine kinases and include angiopoietins, ephrins,
and ﬁbroblast growth factors [9,10].
The LSEC phenotype is also regulated by biomechanical forces
such as shear stress. The most prominent effect of shear stress
appears to be in the modulation of endothelial nitric oxide syn-
thase (eNOS) activity in LSECs, thereby regulating ﬂow and vascu-
lar tone in the sinusoids [11]. Exposure of cultured LSECs to
varying degrees of ﬂow leads to different degrees of eNOS activa-
tion and NO release [11]. Similarly, isolated perfused rat livers
increased NO release as a result of shear stress [11].
LSEC-mediated paracrine regulation. Not only do exogenous fac-
tors play an important role in the regulation of the LSEC phe-
notype, but recent evidence indicates that LSECs themselves
play an important role in the function of neighbouring cells
and, therefore, the microenvironment. For example, LSECs pro-
duce angiocrine growth factors and regulate liver regeneration
and ﬁbrosis. Wnt2 and hepatocyte growth factor (HGF) induced
by LSECs promote hepatocyte proliferation [12]. It has also
been reported that bone marrow-derived LSEC progenitor cells
are important for liver regeneration because of the large por-
tion of HGF they induce [13]. Interestingly, however, LSECs iso-
lated from biliary cirrhotic mice exhibit enhanced pro-ﬁbrotic
growth factors and cytokines, such as transforming growth fac-
tor (TGF)-b, bone morphogenetic protein 2(BMP2) and platelet
derived growth factor (PDGF)-C, with decreased anti-ﬁbrotic4 vol. 61 j 912–924
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factors such as follistatin and apelin [14]. Furthermore, LSECs
may release vesicles, including ‘‘microvesicles’’ (also referred
to as ‘‘microparticles’’) and exosomes; these structures appear
to contain signaling molecules that regulate other cell types
in a paracrine fashion [15]. Our understanding of both struc-
tures is at a nascent state but increasing information indicates
a role in paracrine signaling. Interestingly, recent studies indi-
cate that growth factor stimulation of endothelial cells may
stimulate release of these ‘‘signaling vesicles.’’ One such growth
factor may be the ﬁbroblast growth factor (FGF). While less
studied than VEGF in the hepatic microcirculation, FGF signal-
ing through its cognate receptor FGFR is important for LSEC
stimulatory signaling and release of paracrine molecules [9].
These features are pertinent not only in physiologic conditions
but also in pathophysiologic situations, such as cirrhosis and
portal hypertension as discussed below.
LSECs also appear to be an important source of certain
types of extracellular matrix. For example, LSECs produce the
cellular isoform of ﬁbronectin in response to injury [16]. Fibro-
nectin in turn has potent paracrine effects on hepatic stellate
cells (HSCs) [16], stimulating their activation early in the injury
process. Additionally, ﬁbronectin appears to stimulate HSC
synthesis of endothelin-1 (ET-1), which in turn has paracrine
effects on HSCs [17].
LSEC phenotype in disease. During liver injury, the LSEC phenotype
changes dramatically [1]. One of the most remarkable phenotypic
changes is ‘‘capillarisation’’, characterised by loss of fenestrae and
abnormal deposition of a basement membrane matrix on the
abluminal surface of LSECs [1]. In addition to these anatomical
changes, a number of biochemical changes also occur in the LSEC
phenotype. For example, it is now well established that eNOS
activity is diminished in LSECs after liver injury, consistent with
an endothelialopathy in liver disease [5,18]. This has a number
of important effects on portal hypertension, including that a
reduction in intrahepatic NO appears to be a critical component
of the intense vasoconstrictive nature of the injured liver [19].
The mechanism for the reduction in eNOS activity and NO
synthesis after injury is tied to extensive post-translational dys-
regulation of eNOS. For example, it has been established that
eNOS function is tied to a series of events that regulate the phos-
phorylation status of eNOS, including by interacting and/or bind-
ing to calmodulin, caveolin-1, HSP90, Akt, and a variety of other
intracellular proteins [20,21]. In the liver increased expression
of caveolin-1 in LSECs appears to be important in the reduced
eNOS activity described [5]. More recent work suggests that a
series of complex molecular events, involving molecules that reg-
ulate and/or dampen G protein coupled receptor signaling,
potently modulate eNOS [22,23].
Reduced NO from LSECs may also play a role in progression of
ﬁbrosis. NO has been shown to maintain quiescence of hepatic
stellate cells (HSCs) and reduced exposure of HSCs to NO may
facilitate their activation [24,25].
As mentioned above, VEGF is important in the maintenance of
LSEC fenestrae and may prevent LSECs from undergoing capillar-
isation [6–8]. The mechanism of this effect is currently unknown.
However, there may be a role for VEGF in NO signaling in LSECs,
and it is possible that VEGF’s downstream NO signaling plays an
important role in the maintenance of LSEC fenestrae [26].
Neighbouring cells also appear to change the LSEC pheno-
type in disease. For example, in response to a treatment withJournal of Hepatology 201saturated free fatty acids in vitro, which mimics lipid accumu-
lation in steatosis, hepatocytes release microvesicles that have
pro-angiogenic activity [27]. Microvesicles collected from con-
ditioned media from these lipid-challenged hepatocytes
enhanced migration and tube formation of endothelial cells
in vitro. Although the effects of these hepatocyte-derived micr-
ovesicles on LSECs have not been clearly speciﬁed, these obser-
vations suggest that the hepatocyte-LSEC communication
induces angiogenesis.
Pericytes, stellate cells, and myoﬁbroblasts
By virtue of their anatomic position in the sinusoid (Fig. 2), stel-
late cells have also been coined liver speciﬁc pericytes. Pericytes
are found throughout the body in small calibre blood vessels, typ-
ically capillaries [28]. They exhibit many features of smooth mus-
cle cells and are believed to play a role in blood ﬂow regulation.
Recent work has suggested that their role may be more complex,
and that they have more pleiotropic roles, in particular in wound
healing; here they differentiate into cells with other functions
[29,30]. For example, fate mapping experiments in several
organs, including the liver, indicate that pericytes are the cellular
precursors of myoﬁbroblasts (see below) and transform in
response to injury [29,30].
Current evidence indicates that during wound healing, stellate
cells undergo a transformation process. This process, termed
‘‘activation’’, involves a number of complex and integrated fea-
tures. Characteristics of activation include morphologic and func-
tional changes, such as loss of vitamin A, acquisition of stress
(actin) bundles, development of a prominent rough endoplasmic
reticulum, and production of increased quantities of extracellular
matrix [31]. One of the most prominent features of stellate cell
activation is an increase in the expression of smooth muscle a
actin. Thus, these data point to stellate cells as liver speciﬁc myo-
ﬁbroblasts. Myoﬁbroblasts appear to be key elements in the
wounding response to injury in many tissues, producing abun-
dant quantities of extracellular matrix, as well as smooth muscle
proteins [32–36]. The functional role of myoﬁbroblasts in the
liver is most likely tied to ﬁbrogenesis, and thus indirectly linked
to portal hypertension, since it is believed that both perisinusoi-
dal and bridging scar formation contributes to portal hyperten-
sion at the sinusoidal level, and perhaps at the whole liver
level, respectively.
From a cell biological and molecular signaling pathway, the
upregulation of smooth muscle a actin in the activation process
is complex, and involves interplay between stellate and other
cells, cytokines and other soluble elements, and the extracellular
matrix itself. Having said that, there appear to be some parallels
between the regulation of smooth muscle a actin and ﬁbrogene-
sis, the latter being a major component of the activation process.
For example, transforming growth factor beta-1 (TGF-b1) the
most proﬁbrogenic cytokine for stellate cells, may also regulate
smooth muscle a actin gene expression [37]. Recent evidence
indicates that smooth muscle a actin expression in stellate cells
is controlled transcriptionally by canonical muscle speciﬁc tran-
scription factors, including serum response factor [38]. Further,
it appears that there may be interplay between the smooth mus-
cle a actin cytoskeleton and various stellate cell functions,
including cell motility and contractility [39]. These data indicate
that smooth muscle a actin itself is not a static component of the
cytoskeleton, but rather a dynamic regulator of stellate cell
behaviour and function.4 vol. 61 j 912–924 915
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Fig. 2. Changes in the hepatic sinusoid in response to liver injury. (A) shows a simpliﬁed version of a portal tract (left), central vein (right), and hepatic sinusoidal
morphology with associated cell types within the sinusoid. (B) shows the sinusoid in response to liver injury; the upper panel depicts a cross sectional image, while the
lower panel shows a 3-dimensional view. In the normal state (left), sinusoidal endothelial cells produce NO supporting a low resistance state. In response to liver injury,
extensive changes occur in the sinusoid. Liver injury (right) leads to both morphological as well as molecular abnormalities in sinusoidal endothelial cells and stellate cells.
For example, endothelial cells become defenestrated, develop a defect in NO production, and concurrently increase production of other proteins such as endothelin and
ﬁbronectin that can contribute to stellate cell activation. Upon their activation, stellate cells develop an enhanced contractile phenotype and produce increased extracellular
matrix. A number of paracrine and autocrine interactions occur between sinusoidal endothelial cells and stellate cells with some of the putative molecules and their
associated functions shown (gray box). HSC, hepatic stellate cells; LSEC, liver sinusoidal endothelial cell.
ReviewSinusoidal vascular remodelling
Sinusoidal vascular remodelling involves a complex interplay of
hepatic cells and appears to contribute to increased intrahepatic916 Journal of Hepatology 201resistance. For example, when quiescent HSCs become activated
and start to deposit extracellular matrix proteins this creates a
basement membrane around the sinusoids. In turn vigorous
‘‘coverage’’ of the sinusoids with activated HSCs could contribute4 vol. 61 j 912–924
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Fig. 3. Sprouting and intussusceptive angiogenesis in cirrhosis and portal
hypertension. Normal architecture of sinusoidal vasculature is shown in left
panel with normal ﬂow from portal venules, through sinusoidal microcirculation,
to central veins. The sinusoidal vasculatures in the cirrhotic livers (right panel)
are altered signiﬁcantly, with increased number of sinusoidal vessels (angiogen-
esis) of various diameters and ﬂow pattern. This is a simpliﬁed diagram of the
sinusoidal microcirculation in liver cirrhosis. In cirrhosis, however, the relation-
ship between the portal and central veins is not maintained because of ﬁbrous
septa and regenerative nodules, which disrupt the normal vascular architecture of
portal venules, sinusoid and central vein. In sprouting angiogenesis, it is proposed
that an endothelial ‘tip cell’ leads the vessel sprouts at the forefront and a trailing
endothelial ‘stalk cell’ elongates behind the tip cell of a growing branch of vessels.
Intussusceptive angiogenesis involves splitting vessels by the formation of
translumenal pillars. Both forms of angiogenesis require the recruitment of
pericytes or smooth muscle cells (SMCs). In cirrhotic livers, activated hepatic
stellate cells (HSCs) are thought to serve as a role of pericytes and SMCs.
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to increased intrahepatic resistance in cirrhotic livers [40].
Furthermore, with injury, reduced LSEC NO production appears
to stimulate cell proliferation, upregulates various arterial surface
markers and contributes to loss of LSEC fenestrations, resulting in
de-differentiation and capillarisation of the hepatic microvascu-
lar bed [41]. These changes facilitate remodelling and constric-
tion of the sinusoidal vasculature, which increases hepatic
vascular resistance and is an early feature of intrahepatic portal
hypertension.
Angiogenesis
Angiogenesis, the process of new blood vessel formation from
pre-existing vascular beds, takes place in two distinctive man-
ners, namely through sprouting from the existing vasculature
or splitting of the existing vasculature. In sprouting angiogenesis,
angiogenic growth factors, through activation of endothelial cells,
facilitate the degradation of the basement membrane in pre-
existing blood vessels, which allows endothelial cells, pericytes
and smooth muscle cells to detach and migrate towards angio-
genic stimuli (Fig. 3). Endothelial cells then proliferate and form
solid sprouts connecting neighbouring sprouts or blood vessels.
Endothelial cells ﬁnally stop proliferating and bind to each other,
to the pericytes and to the basement membrane, forming a new
blood vessel [42,43]. Sprouting angiogenesis appears to involve
a complex interplay between numerous signalling pathways such
as Notch and Notch ligands, vascular endothelial growth factor
(VEGF) and VEGF receptors (VEGFRs), semaphorins, and netrins
[44], while signaling pathways regulating intussusceptive angio-
genesis are less well studied but include Notch, Notch ligands,
Tek/Tie-2, mTOR, ephrins and Eph receptors [45].
Intussusceptive angiogenesis, also known as splitting angio-
genesis, was discovered relatively recent as an alternative process
[46]. In intussusceptive angiogenesis, the two opposing walls of a
capillary extend towards each other and form an intraluminal pil-
lar. The cellular junctions of opposing endothelial cells are reor-
ganised, which facilitates further growth of the pillar and
ﬁnally results in splitting of the capillary into two new vessels
[47]. Intussusceptive angiogenesis relies less on endothelial cell
proliferation and generates blood vessels more rapidly [44,48].
Therefore, intussusceptive angiogenesis is particularly important
in embryonic development where pre-exiting blood vessels are
limited to create new vessels [49].
Both forms of angiogenesis, sprouting and intussusceptive,
appear to be important in normal liver physiology and in patho-
physiologic states, including liver organogenesis [50,51], liver
regeneration [12,52], chronic liver diseases with ﬁbrosis [53],
nodular regenerative hyperplasia [45], hepatocarcinogenesis
[54], and tumour angiogenesis [45].
Angiogenesis in the intrahepatic circulation
In portal hypertension, angiogenesis plays a crucial role in both
intra and extra hepatic circulations. In the intrahepatic circula-
tion, for example, it is reported that conditional Notch 1 knockout
mice develop intussusceptive angiogenesis, nodular regenerative
hyperplasia and portal hypertension. LSECs from these mice show
reduced endothelial fenestrae. These observations indicate that
Notch1 in LSEC is required for fenestration of LSECs and the loss
of Notch 1 results in pathological intussusceptive angiogenesis
and the development of nodular regenerative hyperplasia and
portal hypertension [45]. Irregular ﬂow patterns generated as aJournal of Hepatology 201result of intussusceptive angiogenesis might contribute to an
increase in resistance within the intrahepatic circulation, leading
to portal hypertension.
Furthermore, angiogenesis occurring after liver injury appears
to increase the vascular volume in response to inﬂammation and
hypoxia induced in the ﬁbrogenic process [55]. Histological4 vol. 61 j 912–924 917
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analyses of cirrhotic livers indicate an increased number of ves-
sels in the ﬁbrotic septa and surrounding regenerative nodules
[56]. This observation has led to the hypothesis that activated
HSCs and/or other myoﬁbroblasts such as portal myoﬁbroblasts
promote angiogenesis in liver cirrhosis. In fact, activated HSCs
are known to enhance activation of LSECs by releasing angiogenic
factors, such as angiopoietins [10,40,57] and VEGF [58].Mesenteric vascular pathophysiology
In portal hypertension, increased portal blood inﬂow from the
splanchnic circulation augments portal pressure and thereby
contributes to the maintenance and exacerbation of portal hyper-
tension. Arterial vasodilation in the splanchnic circulation plays a
critical role in increasing the blood ﬂow to the portal vein. To
ameliorate portal hypertension, therefore, blocking arterial
vasodilation in the splanchnic circulation is necessary. Further,
blocking the development of collaterals could be useful for
decreasing the incidence of portosystemic encephalopathy and
variceal bleeding.
Vasodilation in the mesenteric vasculature
Arterial vasodilation in the splanchnic and systemic circulations
is an important feature of portal hypertension. Splanchnic arterial
vasodilation increases the blood inﬂow to the portal system and
exacerbates portal hypertension. Splanchnic arterial vasodilation
is attributed to abnormal cell function in different layers of the
vasculature, namely, endothelial cells, smooth muscle cells and
the adventitial layer that contains neuronal termini. Because of
the disparate regulation of the vascular tone in the intrahepatic
and extrahepatic circulations (i.e., vasoconstriction in the intra-
hepatic circulation vs. vasodilation in the extrahepatic circula-
tion), the organ/tissue speciﬁc modulation of the vasodilator
molecules is of paramount importance.
Increased vasodilator molecules in endothelial cells
eNOS-derived NO is increased in the splanchnic and systemic cir-
culation and plays a principal role in arterial vasodilation. Com-
plex regulatory mechanisms of eNOS activation appear to be
important in these pathological vasculature structures. For exam-
ple, a recent study [59] described a new mechanism for the mod-
ulation of eNOS in cirrhosis, which involves the renin-angiotensin
(Ang) system. The renin-Ang system plays a critical role in blood
pressure control, body ﬂuid and electrolyte homeostasis. Angio-
tensin II is a vasoconstrictor generated by the action of angioten-
sin-converting enzyme (ACE) and is further cleaved by ACE2 to
generate a biologically active peptide, Ang-(1-7). Ang-(1-7) is
however a vasodilator, which binds to the G-protein coupled
receptor Mas (MasR) [60] and leads to eNOS activation and NO
production in endothelial cells [61]. In an animal model of cirrho-
sis, expression of ACE2 and MasR in mesenteric arteries and
Ang-(1-7) production in mesenteric arterial beds was increased
in an ACE2 dependent manner [59]. Furthermore, Ang-(1-7)/
MasR contributed to vasodilation in mesenteric arterial beds of
cirrhotic rats, suggesting that NO might mediate this
vasodilation.
Of note, NO may also contribute to the regulation of lymphatic
ﬂow by modulating smooth muscle cell contractility [62]. For
example, mesenteric lymphatic vessels in cirrhotic rats were918 Journal of Hepatology 201found to have increased endothelial cell eNOS expression and
decreased smooth muscle cell coverage [63]; this diminished
smooth muscle cell coverage was reversed by inhibition of eNOS.
These and other data emphasise the importance of the lymphatic
vascular system in liver diseases [64].
Besides NO, other vasodilator molecules, such as CO, prostacy-
clin (PGI2), adrenomedullin, endocannabinoids and endothelium-
derived hyperpolarising factors (EDHF), also mediate arterial
vasodilation. Some controversy surrounds the identity of EDHF
in the hepatic system [65]. Candidate molecules include arachi-
donic acid metabolites (epoxyeicosatrienoic acid [EET]), the
monovalent cation K+, components of gap junctions, and hydro-
gen peroxide. A recent study showed that in small resistance
mesenteric arteries of cirrhotic rats, an arachidonic acid metabo-
lite (11,12-EET) and gap junctions (in particular connexins 40 and
43) mediate increased vasodilation in the splanchnic circulation
[66]. Collectively, the data suggest that multiple factors are
involved in the excessive vasodilation, observed in the splanchnic
and systemic circulations (Fig. 4).
Smooth muscle cell hypocontractility
Concomitant with vasodilation, splanchnic and systemic arteries
exhibit decreased contractile response to vasoconstrictors. This is
caused not only by increases in vasodilator molecules mentioned
above, but also by impaired contractile RhoA/Rho-kinase signal-
ing in smooth muscle cells (see [67] for further review) and
sympathetic nerve regression in these arteries [68]. A variety of
vasoconstrictor molecules are also decreased in smooth muscle
cells in the arteries of the splanchnic and systemic circulations;
these include neuropeptide Y [68], urotensin II [69,70], angioten-
sin [71] and bradykinin [72,73]; this sets up impairment of con-
tractility in the mesenteric vasculature in portal hypertension.
Arterial thinning
Vascular remodelling of the mesenteric vascular bed is another
major event in portal hypertension. In a murine model of liver
cirrhosis with portal hypertension, the thinning of arterial walls
is observed in the splanchnic and systemic circulations [74,75].
Arterial walls consist of endothelial cells, smooth muscle cells
and adventitia. The cellular and molecular mechanisms responsi-
ble for arterial thinning remain to be fully elucidated. One
hypothesis is that increased apoptosis of smooth muscle cells in
the mesenteric artery leads to thinning [76]. Through these struc-
tural changes as well as possible changes in the levels of proteins
important for arterial integrity and function, arterial thinning
may help to impair contractile responses of the arteries. Further,
arterial thinning may contribute to increased permeability
through structural and compositional changes in vessel junctions
and thereby facilitate the development of ascites and oedema.
Thus, arterial thinning that results from hemodynamic changes
caused by portal hypertension may further help to sustain arte-
rial vasodilation and worsen portal hypertension [65,77].
Extrahepatic collateral vessel formation
Porto-systemic collaterals (or shunts) develop through the open-
ing of pre-existing vessels in response to an increase in portal pres-
sure [78,79]. Changes in portal pressure are sensed ﬁrst by the
intestinal microcirculation and then by arteries of the splanchnic
circulation [80]. It also appears that these vascular beds in turn4 vol. 61 j 912–924
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Fig. 4. Mechanisms of increased vasodilation in arteries of the splanchnic circulation in cirrhosis with portal hypertension. In the splanchnic arterial circulation,
agonists such as vascular endothelial growth factor (VEGF) and Ang(1-7) or physical stimuli such as shear stress activate endothelial nitric oxide (NO) synthase (eNOS). In
cirrhosis, Ang(1-7) levels are signiﬁcantly increased by upregulation of angiotensin-converting enzyme (ACE)-2. In addition, MasR, a receptor of Ang(1-7) is up-regulated in
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activating soluble guanylate cyclase (sGC) to generate cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells. Prostacyclin (PGI2) is synthesised by
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connexins (Cx) 40 and 43].
JOURNAL OF HEPATOLOGYproduce various angiogenic factors, such as VEGF [81–83] and pla-
cental growth factor (PlGF) [84], which stimulate angiogenesis
and promote the formation of portosystemic collaterals. Using a
vascular corrosion technique, it was demonstrated that collaterals
are formed in the splanchnic circulation in portal hypertensive
mice by both sprouting and intussusceptive angiogenesis [85].
Collaterals develop to decompress the portal system. How-
ever, portal pressure remains elevated because of increased
splanchnic blood ﬂow resulting from splanchnic vasodilation.
Additionally, these collaterals cause serious complications such
as variceal bleeding and hepatic encephalopathy [65]. To what
extent collaterals develop through the opening of pre-existing
vessels, sprouting and intussusceptive angiogenesis remains an
active area of investigation.
Studies in experimental models of portal hypertension and cir-
rhosis have shown that portal systemic collaterals can be reduced
by a variety of approaches, including inhibiting VEGF (with anti-
VEGFR2) or a combination of anti-VEGF (rapamycin)/anti-platelet
derived growth factor (PDGF) (gleevec), PlGF [84], apelin [86],
sorafenib [87,88] and cannabinoid signaling [89]. However, the
reduction of collateral vessels does not always result in a decrease
in portal pressure to the normal level, since this reduction does not
signiﬁcantly change the portal blood ﬂow [84,90].
Translational implications and future directions
Much has been learned in the area of hepatic vascular biology in
the last decade, and this new information holds great promise for
the development of novel therapies for patients with portalJournal of Hepatology 201hypertension. Based on an understanding of vascular pathology
in chronic liver disease and portal hypertension, many potential
therapies are evolving (Table 1). Here, as examples, we review
three speciﬁc potential biological systems and associated
therapies.
Statins and intrahepatic resistance
The statin class of compounds has gained considerable interest in
vascular biology and in portal hypertension because they appear
to stimulate eNOS and activate endothelial NO production [91]. It
is also possible that statins may stimulate downstream signaling
molecules that have beneﬁcial effects in the liver. One mecha-
nism of statins appears to be via selective effects on LSECs
through stimulation of the expression of the KLF2 transcription
factor [92,93]. KLF2 is highly expressed in vascular endothelial
cells and protects the endothelium by upregulating the expres-
sion of a wide variety of vasoprotector genes [94,95], including
eNOS [96]. Interestingly, LSECs overexpressing KLF-2 lead to
HSC quiescence when these cells are co-cultured, suggesting that
the statins’ anti-ﬁbrogenic effect through up-regulation of KLF-2
is LSEC mediated [93]. However, statins may also exert their
anti-ﬁbrotic effect via direct activity on HSCs. Early atorvastatin
exposure in a rat model of hepatic ﬁbrosis attenuated HSC activa-
tion and ﬁbrosis [97]; additionally, atorvastatin induced senes-
cence in hepatic myoﬁbroblasts in vitro and in vivo [98].
It has also been documented that atorvastatin decreases
portal pressure in cirrhotic rats by inhibiting Rho-kinase and by
activating eNOS [91]. Rho-kinase contributes to increased intra-4 vol. 61 j 912–924 919
Table 1. Target molecules and experimental approaches/drugs that are reported to decrease portal pressure. (See below-mentioned references for further information.)
Target molecules Approaches/drugs
Intrahepatic circulation
Nitric oxide (NO)/endothelial NO synthase (eNOS) Statins [111], eNOS gene transfer [112], neuronal NOS gene transfer [113], 
Akt gene transfer [114], tetrahydrobiopterin (BH4) [115,116]
TXA2 COX-1 inhibitor (SC-560) [117], PGH2/TXA2 receptor blocker (SQ-29548) 
[118]
Superoxide radicals Antioxidants: vitamin C [119], vitamin E [120], superoxide dismutase (SOD) 
gene transfer [121], SOD mimetic [121,122], N-acetylcysteine [123]
Hydrogen sulfide (H2S) Sodium hydrogen sulfide [124]
Notch 1 Notch 1 KO mice [79]
Nogo-B Nogo-B KO mice [125]
Toll like receptor 4 TLR4 mutant mice [126]
The farnesoid-X-receptor (FXR) A selective FXR agonist, obeticholic acid (INT-747) [102]
Splanchnic and systemic circulation
Cannabinoid receptor type 2 (CB2) receptor CB2 receptor agonist (JWH-015) [89]
RhoA/Rho-kinase Neuropeptide Y [68]
Peroxisome proliferator-activated receptor gamma 
(PPARγ)
PPARγ agonist (pioglitazone) [127]
Vascular endothelial growth factor (VEGF) Anti-VEGFR2 monoclonal antibody (SU5416) [82,128], receptor tyrosine 
kinase inhibitors (sorafenib [87,88], sunitinib [129])
Placental growth factor (PIGF) PlGF KO mice and anti-PIGF monoclonal antibody [84]
Apelin Apelin antagonist (F13A) [86]
Reviewhepatic resistance in cirrhosis, by mediating contraction of acti-
vated HSCs. Further, HSC-speciﬁc inhibition of Rho-kinase
decreased intrahepatic resistance and lowered portal pressure
in an experimental model [99].
Initial studies have indicated that statins can reduce portal
pressure in cirrhotic patients and clinical trials are ongoing in
patients with cirrhosis that are aimed at identifying a clinical
niche for statins [100].
Obeticholic acid
Obeticholic acid is a semisynthetic bile acid analogue and a
potent selective farnesoid-X receptor agonist [101]. A recent
study demonstrated that obeticholic acid decreased intrahepatic
resistance and ameliorated portal hypertension in both thioaceta-
mide (TAA) treated – and bile duct ligated rats, by increasing
intrahepatic eNOS activity through down-regulation of Rho-
kinase and through up-regulation of dimethylarginine dimethyl-
aminohydrolase 2(DDAH-2), respectively [102].
VEGF
A number of preclinical studies support the concept that inhibi-
tion of VEGF may have beneﬁcial therapeutic effects in portal
hypertension. Mechanisms by which VEGF inhibition may be
beneﬁcial include attenuation of mesenteric angiogenesis and
portosystemic collaterals as well as reduction in intrahepatic vas-
cular remodelling and ﬁbrogenesis. Additional effects of VEGF
inhibition on reduction in vascular permeability and ascites are
also documented [103]. However, further studies are needed in
humans and this is being pursued in an indirect manner through
analysis of small molecule inhibitors of receptor tyrosine kinases
such as sorafenib (with the understanding that these inhibitors
target a multitude of receptor tyrosine kinases on different cell920 Journal of Hepatology 201types) [10,104]. It should be pointed out that based on data with
VEGF inhibition in the cancer arena, unanticipated effects of VEGF
inhibition may be possible. Furthermore, some data indicate that
VEGF itself may be important in hepatic tissue healing, sinusoidal
normalisation, and regeneration. For example, VEGF may induce
ﬁbrosis regression through effects on macrophage inﬁltration
and ensuing matrix degradation [105]. Further, in one study, re-
establishment of LSEC fenestrae via restoration of VEGF function
fully reversed portal hypertension and its secondary manifesta-
tions [8]. Finally, VEGF facilitates the recruitment of bone mar-
row-derived LSEC progenitor cells during liver regeneration
[106]. Thus, the role of VEGF in liver injury, ﬁbrosis, and portal
hypertension, as well as its role in the recovery from these pro-
cesses will require further exploration.
Future
Here, we have reviewed current concepts in the area of intra- and
extra-vascular pathophysiology in portal hypertension. A number
of novel areas are on the horizon. For example, an attractive
future area will likely include inter-organ relationships in the
pathogenesis of portal hypertension in the context of vascular
biology. An excellent example in portal hypertension will be
the gut-liver axis. The importance of bacterial translocation from
the gut to the portal circulation has been long recognised in the
study of portal hypertension, but the molecular basis of this
relationship has been little investigated. The vascular biology
associated with the gut-liver axis, including an understanding
of how TLR signaling to key cellular players is initiated, or how
vascular permeability may be changed facilitating bacterial trans-
location, will be important.
An understanding of VEGF function in the liver and mesen-
teric circulation is just now coming into focus. VEGF has different
isoforms and distinct VEGF receptors mediate a variety of4 vol. 61 j 912–924
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signaling cascades in cell speciﬁc manners [107]. Therefore, a
detailed characterisation of VEGF induced pathways is needed
to understand the intra- and extra-hepatic neovascularisation
in portal hypertension. In addition, angiocrine growth factors in
addition to VEGF are likely to play a role in the neovascularisation
typical of portal hypertension and will be important.
An accumulating body of evidence suggests that neovascular-
isation is a key pathological feature of patients with non-alco-
holic steatohepatitis (NASH) [108]. In mouse models of NASH,
treatment with anti-mouse VEGFR2 antibody improved disrupted
liver vasculature, decreased inﬂammatory gene expressions, and
reduced steatosis to some extent, suggesting that VEGF is
involved in the pathogenesis of NASH [109]. However, the
mechanisms underlining hepatic neovascularisation in NASH
are largely unknown and are important for investigation.
Other unexplored, but yet important areas include the role of
the extracellular matrix components and their signaling in the
vascular cells such as integrins as well as that of non-coding RNAs
in portal hypertension. In particular, certain extracellular matrix
components may have an important role in vascular remodelling
associated with portal hypertension, as suggested by a recent
study emphasising the role of integrins in ﬁbrosis in several
organs, including the liver [110].
Finally, available data suggest that the pathogenesis of portal
hypertension is linked to speciﬁc and targetable molecular
pathways. This suggests that approaches exist for manipulating
these pathways. For example, correcting the defect in eNOS
signaling in intrahepatic LSECs is attractive. Alternatively,
abrogating the effect of the abundant vasoconstrictors in the
intrahepatic circulation, or approaching neoangiogenesis in the
mesenteric circulation would be therapeutically attractive.
Indeed, the prospects for new therapy in the area of vascular
biology of the liver are bright.Financial support
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